|Kintor Pharma||Kintor Pharmaceutical Limited is a HK-listed (HK.9939) pharmaceutical company with its main office in Suzhou, China. The company is focused on cancers and other high-incidence diseases to fulfill unmet medical needs.|
Our particular expertise is in developing therapies for androgen receptor-related diseases, including Proxalutamide for COVID-19 (Phase 3), Pyrilutamide (KX-826) for androgenetic alopecia (Phase 3 to be started) and Acne (Phase 1b). We also focus on anti-angiogenetic therapies for cancers and other related diseases, including an ALK1 mAb GT90001 for HCC (combined with PD-1, Phase 2), PD-L1&TGF-β (GT90008), etc.
We are looking for ex-China partnership for Proxalutamide and Pyrilutamide, and are extensively looking for in-license opportunities.
|Virogin||Virogin Biotech is a clinical-stage oncolytic virus company focused on novel engineering of the herpes simplex virus (HSV-1) to generate strong and durable anti-tumor immune response against solid tumors. Our lead program, VG161, is an oncolytic HSV-1 designed to encode a novel combination of cytokines (IL12/IL15/IL15RA) and a PD-L1 blocking peptide that together induces a robust cytotoxic immune response and leads to systemic anti-tumor effects. We are also developing an oncolytic HSV-1 that is uniquely engineered to enhance tumor-specific replication and payload expression. Due to the high payload capacity to include additional transgenes, we have developed a differentiated HSV-1 oncolytic virus platform with the ability to design multiple therapeutic products.|
|Purple Biotech||The company is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) or colorectal adenocarcinoma in a phase 1/2 study, and an expansion phase of NT219 at its recommended phase 2 level in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1b study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer.|
|CARsgen Therapeutics||CARsgen is a clinical-stage biopharmaceutical company with operations in China and the U.S. focused on innovative CAR-T cell therapies for the treatment of solid tumors and hematological malignancies. Founded in 2014 in Shanghai, CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR-T cell therapies, such as enhancing the efficacy in treating solid tumors, improving the safety profile and reducing treatment costs.|
|Oncolys BioPharma Inc.||The company continuously evolve its business to develop|
breakthrough therapy and diagnostics in cancer treatment from early to late stage, including early detection, loco-regional therapy, prognostic test, and systemic treatments.
|Immunophage||Immunophage Biomedical Co Ltd. is a global-clinical stage biopharmaceutical company focusing on innovating and developing the next generation drug for unmet medical needs. Founded and managed by seasoned executives in the biopharma industry, Immnophage is backed by many renowned investors. The company has developed a pipeline of globally innovative molecules, covering a wide range of innovative targets with a particular focus on oncology, autoimmune diseases, metabolic and neurodegenerative diseases. The company has built strong capability for both small and large molecular platforms. Based on our own platform and effort, currently, we have two self-developed assets in clinical stage (IPG1094 and IPG7236). Meanwhile, we have a number of global leading innovative molecules under research and development. The company endeavors to advance at least two potentially innovative and differentiated global molecules into the clinic each year, providing clinical benefits to patients worldwide. We have established a Shanghai R&D center, a wholly-owned subsidiary in Australia and a wholly-owned subsidiary in the United States to realize the layout of globalization since 2018. The company was recognized as a national high-tech enterprise in 2020 and selected as a cultivated unicorn enterprise in Nanjing in 2021.|
|Lytix Biopharma||Lytix Biopharma, a clinical stage biotech company headquartered in Oslo, Norway, has developed proprietary non-viral oncolytic molecules as a novel in situ vaccination principle in cancer immune therapy|
|FivepHusion||FivepHusion is an Australian biotechnology company commercialising Deflexifol™, an optimised formulation of the cancer drugs 5-fluorouracil (5-FU) and leucovorin (LV) as a new foundation for solid tumour cancer therapy.|
|AI Therapeutics||AI Thera was founded in 2013 and is focused on the development and commercialization of rare & orphan disease drugs.|